NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT04752813 2026-01-26
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
Phase 2 Active not recruiting
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT01587144 2021-10-19
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02202993 2019-07-24
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
Cavion
Phase 1 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00684567 2017-06-07
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01220271 2017-02-16
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Eli Lilly and Company
Phase 1/2 Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00723827 2015-01-30
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
Completed
NCT00115453 2008-08-18
Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma
Boneca Corporation
Phase 1/2 Terminated